Myhibbin FDA Approval History
FDA Approved: Yes (First approved May 1, 2024)
Brand name: Myhibbin
Generic name: mycophenolate mofetil
Dosage form: Oral Suspension
Company: Azurity Pharmaceuticals, Inc.
Treatment for: Organ Transplant, Rejection Prophylaxis
Myhibbin (mycophenolate mofetil) is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection.
- Myhibbin is indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.
Development timeline for Myhibbin
| Date | Article |
|---|---|
| May 6, 2024 | Approval FDA Approves Myhibbin (mycophenolate mofetil) Oral Suspension for Prophylaxis of Organ Rejection |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
